SEATTLE & NEW YORK--(BUSINESS WIRE)--Nov. 14, 2005--Targeted Genetics Corporation (NASDAQ:TGEN) and The International AIDS Vaccine Initiative (IAVI) today announced the start of a Phase II trial in South Africa to test the safety and immunogenicity of tgAAC09, a preventive HIV vaccine candidate that is based on HIV subtype C, the subtype of the virus most prevalent in southern and eastern Africa.
